Enhancing Lesion Detection in Inflammatory Myelopathies: A Deep Learning-Reconstructed Double Inversion Recovery MRI

Qiang Fang1, Qing Yang1, Bao Wang1

  • 1From the Department of Radiology (Q.F., Q.Y., B. Wang, J.H.), Qilu Hospital of Shandong University, Jinan, Shandong Province, China.

Abstract

Insights

Deep learning reconstruction for 3D double inversion recovery (DIR) imaging significantly reduces scan time and improves image quality in inflammatory myelopathies. This advanced DIR technique enhances lesion detection without compromising diagnostic confidence, offering a valuable clinical tool.

Area of Science:

  • Radiology
  • Medical Imaging
  • Artificial Intelligence in Medicine

Background:

  • Magnetic resonance imaging (MRI) is crucial for detecting lesions in inflammatory myelopathies.
  • Deep learning (DL) reconstruction's impact on 3D double inversion recovery (DIR) imaging for these conditions is not well-understood.

Purpose of the Study:

  • To compare deep learning-reconstructed DIR (DIRDL) with standard DIR and conventional T2WI for inflammatory myelopathies.
  • The study evaluated acquisition time, image quality, diagnostic confidence, and lesion detection.

Main Methods:

  • An observational study included 149 patients with inflammatory myelopathies.
  • Images acquired included sagittal T2WI, standard 3D DIR, and accelerated DIRDL.
  • Neuroradiologists assessed image quality, SNR, artifacts, and diagnostic confidence using a Likert scale.

Main Results:

  • DIRDL reduced acquisition time by 49% compared to standard DIR (151s vs 298s).
  • DIRDL showed superior overall image quality, perceived SNR, and reduced artifacts (P < .001).
  • DIRDL detected 37% more lesions than T2WI (300 vs 219; P < .001), with no significant difference in diagnostic confidence.

Conclusions:

  • Deep learning reconstruction for 3D DIR significantly shortens scan times and enhances image quality in inflammatory myelopathies.
  • DIRDL improves lesion detection compared to T2WI, proving valuable for clinical practice.
  • DIRDL shows potential for integration into future imaging guidelines for inflammatory myelopathies.